|
1
|
Statistics and Information Department,
Ministry of Health, Labour, and Welfare. Vital Statistics of Japan
2004. Tokyo: Health and Welfare Statistics Association; 2006
|
|
2
|
Katanoda K and Yako-Suketomo H: Comparison
of time trends in stomach cancer incidence (1973–2002) in Asia,
from Cancer Incidence in Five Continents, Vols IV–IX. Jpn J Clin
Oncol. 39:71–72. 2009.
|
|
3
|
Li ZX and Kaminishi M: A comparison of
gastric cancer between Japan and China. Gastric Cancer. 12:52–53.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee H, Yun WK, Min BH, et al: A
feasibility study on the expanded indication for endoscopic
submucosal dissection of early gastric cancer. Surg Endosc.
25:1985–1993. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maehara Y, Orita H, Okuyama T, Moriguchi
S, Tsujitani S, Korenaga D and Sugimachi K: Predictors of lymph
node metastasis in early gastric cancer. Br J Surg. 79:245–247.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai J, Ikeguchi M, Maeta M and Kaibara N:
Micrometastasis in lymph nodes and microinvasion of the muscularis
propria in primary lesions of submucosal gastric cancer. Surgery.
127:32–39. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim DY, Joo JK, Ryu SY, Kim YJ and Kim SK:
Factors related to lymph node metastasis and surgical strategy used
to treat early gastric carcinoma. World J Gastroenterol.
10:737–740. 2004.PubMed/NCBI
|
|
8
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
9
|
Chang AC, Janosi J, Hulsbeek M, de Jong D,
Jeffrey KJ, Noble JR and Reddel RR: A novel human cDNA highly
homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol.
112:241–247. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang AC, Jeffrey KJ, Tokutake Y, et al:
Human stanniocalcin (STC): genomic structure, chromosomal
localization, and the presence of CAG trinucleotide repeats.
Genomics. 47:393–398. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wagner GF, Jaworski EM and Haddad M:
Stanniocalcin in the seawater salmon: structure, function, and
regulation. Am J Physiol. 274:R1177–R1185. 1998.PubMed/NCBI
|
|
12
|
Chang AC and Reddel RR: Identification of
a second stanniocalcin cDNA in mouse and human: stanniocalcin 2.
Mol Cell Endocrinol. 141:95–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishibashi K and Imai M: Prospect of a
stanniocalcin endocrine/paracrine system in mammals. Am J Physiol
Renal Physiol. 282:F367–F375. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang AC, Jellinek DA and Reddel RR:
Mammalian stanniocalcins and cancer. Endocr Relat Cancer.
10:359–373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Law AY and Wong CK: Stanniocalcin-2 is a
HIF-1 target gene that promotes cell proliferation in hypoxia. Exp
Cell Res. 316:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Law AY and Wong CK: Stanniocalcin-2
promotes epithelial-mesenchymal transition and invasiveness in
hypoxic human ovarian cancer cells. Exp Cell Res. 316:3425–3434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bouras T, Southey MC, Chang AC, et al:
Stanniocalcin 2 is an estrogen-responsive gene coexpressed
with the estrogen receptor in human breast cancer. Cancer Res.
62:1289–1295. 2002.
|
|
18
|
Meyer HA, Tölle A, Jung M, et al:
Identification of stanniocalcin 2 as prognostic marker in renal
cell carcinoma. Eur Urol. 55:669–678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamura K, Furihata M, Chung SY, et al:
Stanniocalcin 2 overexpression in castration-resistant prostate
cancer and aggressive prostate cancer. Cancer Sci. 100:914–919.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ieta K, Tanaka F, Yokobori T, et al:
Clinicopathological significance of stanniocalcin 2 gene
expression in colorectal cancer. Int J Cancer. 125:926–931.
2009.
|
|
21
|
Volland S, Kugler W, Schweigerer L,
Wilting J and Becker J: Stanniocalcin 2 promotes invasion and is
associated with metastatic stages in neuroblastoma. Int J Cancer.
125:2049–2057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yokobori T, Mimori K, Ishii H, et al:
Clinical significance of stanniocalcin 2 as a prognostic
marker in gastric cancer. Ann Surg Oncol. 17:2601–2607. 2010.
|
|
23
|
Kita Y, Mimori K, Iwatsuki M, et al:
STC2: a predictive marker for lymph node metastasis in
esophageal squamous-cell carcinoma. Ann Surg Oncol. 18:261–272.
2011. View Article : Google Scholar
|
|
24
|
Arigami T, Natsugoe S, Uenosono Y, et al:
Lymphatic invasion using D2–40 monoclonal antibody and its
relationship to lymph node micrometastasis in pN0 gastric cancer.
Br J Cancer. 93:688–693. 2005.
|
|
25
|
Arigami T, Natsugoe S, Uenosono Y, et al:
Evaluation of sentinel node concept in gastric cancer based on
lymph node micrometastasis determined by reverse
transcription-polymerase chain reaction. Ann Surg. 243:341–347.
2006. View Article : Google Scholar
|
|
26
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer (AJCC).
Cancer Staging Manual. 7th edition. Springer; New York, NY: pp.
6492010
|
|
27
|
Hoon DS, Bostick P, Kuo C, Okamoto T, Wang
HJ, Elashoff R and Morton DL: Molecular markers in blood as
surrogate prognostic indicators of melanoma recurrence. Cancer Res.
60:2253–2257. 2000.PubMed/NCBI
|
|
28
|
Miyazono F, Natsugoe S, Takao S, et al:
Surgical maneuvers enhance molecular detection of circulating tumor
cells during gastric cancer surgery. Ann Surg. 233:189–194. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uen YH, Lin SR, Wu DC, et al: Prognostic
significance of multiple molecular markers for patients with stage
II colorectal cancer undergoing curative resection. Ann Surg.
246:1040–1046. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ignatiadis M, Kallergi G, Ntoulia M, et
al: Prognostic value of the molecular detection of circulating
tumor cells using a multimarker reverse transcription-PCR assay for
cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Clin Cancer Res. 14:2593–2600. 2008. View Article : Google Scholar
|
|
31
|
Cristofanilli M, Budd GT, Ellis MJ, et al:
Circulating tumor cells, disease progression, and survival in
metastatic breast cancer. N Engl J Med. 351:781–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cohen SJ, Punt CJ, Iannotti N, et al:
Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krebs MG, Sloane R, Priest L, et al:
Evaluation and prognostic significance of circulating tumor cells
in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
